Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + bevacizumab neoadjuvant study in cervical cancer
ChiCTR2600135404Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and bevacizumab in Cervical Cancer (CC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Started Oct 2023; status: recruiting.
02
Drugs
adebrelimabbevacizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600135404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135404.